• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Myomo Launches the MyoPro® 2x

    4/30/25 8:05:00 AM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email

    A Major Step Forward in Donning, Fit, and Function - Enhancing User Independence

    Myomo, Inc. (NYSE:MYO), a wearable medical robotics company that offers improved arm and hand function for individuals with upper-limb paralysis and neuromuscular conditions, today announced the launch of the MyoPro 2x, the latest evolution in its flagship MyoPro product line.

    Designed to enhance the user experience, the MyoPro 2x introduces a reimagined approach to donning, empowering users with a more intuitive, efficient, and consistent process to independently put on their device, while improving fit and function, which is expected to lead to enhanced clinical outcomes.

    "Our goals for these enhancements were primarily clinical. The product development process was driven by inputs from users and clinicians, along with Myomo's own product performance data. This patient and clinician focus was generated from the knowledge gained from over 3000 patients who have received a MyoPro," said Malcolm Bock, Myomo's V.P. Engineering and Product Strategy. "The MyoPro 2x is our best product yet, and we are excited for the significant patient impact of this launch."

    Highlights of the MyoPro 2x include streamlined and more intuitive donning for a consistent fit for the patient, integrating common customizations into the standard design in order to decrease the time for clinicians to fit the MyoPro 2x to their individual patients, and updated training documentation and instruction guides for treating practitioners and users.

    Supporting today's launch, Myomo recently rolled out their full certification process for Orthotic & Prosthetic providers to become MyoPro Centers of Excellence to focus on the MyoPro 2x. This process empowers practices to build their own patient pipelines and, once fully certified, to treat patients with the technology and dispense the MyoPro 2x independently.

    "The MyoPro 2x is about more than innovation—it's about putting independence back into the hands of users," said Paul R. Gudonis, Chairman and CEO of Myomo. "This launch is the result of our commitment to listen to clinicians and users alike and to deliver meaningful improvements that make a real difference in daily life. The MyoPro 2x furthers our leadership in this new and growing space."

    About Myomo, Inc.

    Myomo, Inc. is a medical robotics company that develops and markets advanced myoelectric orthoses to restore function in individuals with neuromuscular disorders and upper-limb paralysis. Myomo's proprietary MyoPro® product line is the only commercial device in the U.S. that, by sensing a patient's EMG signals through non-invasive sensors, can enable individuals to perform daily activities such as eating, lifting objects, and more. Headquartered in Burlington, Mass., Myomo is dedicated to transforming lives through mobility.

    Forward-looking Statements

    Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to Myomo's expectations concerning the MyoPro 2x, including expectations for enhanced clinical outcomes and impact on patients. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Myomo undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Myomo, see the disclosure contained in our public filings with the Securities and Exchange Commission including, without limitation, our most recent Annual Report on Form 10-K.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250430226543/en/

    Media Contact:

    Email: [email protected]

    Phone: 857-283-7543

    Website: www.myomo.com

    Get the next $MYO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Myomo with a new price target

    Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    7/31/24 7:20:07 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Lake Street initiated coverage on Myomo with a new price target

    Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    5/20/24 9:00:38 AM ET
    $MYO
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Myomo with a new price target

    H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

    12/15/23 8:26:14 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myomo Reports Second Quarter 2025 Financial and Operating Results

    Revenue of $9.7 million 816 patients added to the MyoPro pipeline Updates 2025 revenue guidance Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2025. Financial and operating highlights for the second quarter of 2025 include the following (all comparisons are with the second quarter of 2024 unless otherwise indicated): Revenue was $9.7 million, up 28%; 56% of revenue was from Medicare Part B patients. Reven

    8/11/25 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Second Quarter 2025 Financial Results on August 11

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Th

    8/4/25 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Provides Highlights of Today's Investor & Analyst Day Event

    Senior executives to provide an in-depth review of the Company's business model and discuss long-range aspirational financial metrics Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss long-range aspirational financial metrics. A live and archived webcast of the event is available here. To be held

    6/18/25 8:30:00 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $55,000 worth of shares (50,000 units at $1.10), increasing direct ownership by 13% to 424,420 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/19/25 7:23:00 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Chief Executive Officer Gudonis Paul R bought $47,295 worth of shares (50,000 units at $0.95), increasing direct ownership by 4% to 1,259,013 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/18/25 7:51:17 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $125,993 worth of shares (38,767 units at $3.25), increasing direct ownership by 13% to 344,700 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/15/25 4:53:28 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    SEC Filings

    View All

    SEC Form 10-Q filed by Myomo Inc.

    10-Q - MYOMO, INC. (0001369290) (Filer)

    8/11/25 4:15:27 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MYOMO, INC. (0001369290) (Filer)

    8/11/25 4:15:33 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form 144 filed by Myomo Inc.

    144 - MYOMO, INC. (0001369290) (Subject)

    6/30/25 8:12:58 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Financials

    Live finance-specific insights

    View All

    Myomo Reports Second Quarter 2025 Financial and Operating Results

    Revenue of $9.7 million 816 patients added to the MyoPro pipeline Updates 2025 revenue guidance Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2025. Financial and operating highlights for the second quarter of 2025 include the following (all comparisons are with the second quarter of 2024 unless otherwise indicated): Revenue was $9.7 million, up 28%; 56% of revenue was from Medicare Part B patients. Reven

    8/11/25 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Second Quarter 2025 Financial Results on August 11

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Th

    8/4/25 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Provides Highlights of Today's Investor & Analyst Day Event

    Senior executives to provide an in-depth review of the Company's business model and discuss long-range aspirational financial metrics Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss long-range aspirational financial metrics. A live and archived webcast of the event is available here. To be held

    6/18/25 8:30:00 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $55,000 worth of shares (50,000 units at $1.10), increasing direct ownership by 13% to 424,420 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/19/25 7:23:00 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Chief Executive Officer Gudonis Paul R bought $47,295 worth of shares (50,000 units at $0.95), increasing direct ownership by 4% to 1,259,013 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/18/25 7:51:17 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Chief Medical Officer Kovelman Harry covered exercise/tax liability with 13,054 shares, decreasing direct ownership by 8% to 140,618 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    7/2/25 8:20:13 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    10/18/24 2:21:35 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/12/24 10:35:49 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/11/24 6:02:07 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Myomo Appoints Heather Getz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

    3/28/24 4:05:00 PM ET
    $BFLY
    $MYO
    Medical Electronics
    Health Care
    Industrial Specialties

    Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

    1/30/23 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care